60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 16, 2024 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
August 27, 2024 08:00 ET | Soleno Therapeutics
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc....
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2024 16:17 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Updates to its Board of Directors
August 15, 2024 08:00 ET | Soleno Therapeutics
Ernest Mario, Ph.D. steps down as Chair for health reasons; Matthew Pauls, J.D., M.B.A. assumes role of Lead Independent Director Dawn Carter Bir, seasoned biotech executive with significant...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
June 28, 2024 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 24, 2024 17:18 ET | Soleno Therapeutics
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Set to Join Russell 3000® Index
June 04, 2024 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
May 22, 2024 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Participate in Upcoming Investor Conferences
May 22, 2024 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...